These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7020313)

  • 1. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.
    Carmeliet E; Janssen PA; Marsboom R; Van Nueten JM; Xhonneux R
    Arch Int Pharmacodyn Ther; 1978 Jan; 231(1):104-30. PubMed ID: 637616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of lorcainide, a new antiarrhythmic agent, on experimental cardiac arrhythmias].
    Fukuda H; Goto M; Kondo M; Uchigasaki T; Sekino Y
    Nihon Yakurigaku Zasshi; 1983 Feb; 81(2):115-26. PubMed ID: 6852683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of lorcainide.
    Keefe DL
    Am J Cardiol; 1984 Aug; 54(4):18B-21B. PubMed ID: 6465043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of lorcainide during chronic treatment.
    Meinertz T; Kasper W; Kersting F; Bechtold H; Just H; Jähnchen E
    Arzneimittelforschung; 1980; 30(9):1593-5. PubMed ID: 7193031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological characteristics of lorcainide, a new antiarrhythmic drug.
    Solti F; Czakó E; Szatmáry L
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):26-9. PubMed ID: 3957486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.
    Bär FW; Farré J; Ross D; Vanagt EJ; Gorgels AP; Wellens HJ
    Br Heart J; 1981 Mar; 45(3):292-8. PubMed ID: 7470342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles.
    Hattori Y; Hidaka T; Aisaka K; Satoh F; Ishihara T
    J Cardiovasc Pharmacol; 1988 Apr; 11(4):407-12. PubMed ID: 2453743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.
    Somani P
    Am J Cardiol; 1981 Jul; 48(1):157-63. PubMed ID: 7246437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
    Keefe DL; Kates RE; Winkle RA
    J Cardiovasc Pharmacol; 1984; 6(5):808-15. PubMed ID: 6209484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
    Mead RH; Keefe DL; Kates RE; Winkle RA
    Am J Cardiol; 1985 Jan; 55(1):72-8. PubMed ID: 2578245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    Winkle RA; Keefe DL; Rodriguez I; Kates RE
    Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
    Shita A; Bernard R; Mostinckx R; Debacker M
    Eur J Cardiol; 1981; 12(5):237-42. PubMed ID: 7250167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function.
    Somani P; Fraker TD; Temesy-Armos PN
    J Clin Pharmacol; 1987 Feb; 27(2):122-32. PubMed ID: 3680563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmogenic effects of toxic concentrations of the antiarrhythmic drug lorcainide on the isolated canine ventricle.
    Senges J; Rizos I; Brachmann J; Gao TL; Lengfelder W; Kübler W
    J Pharmacol Exp Ther; 1982 Nov; 223(2):547-51. PubMed ID: 7131303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R; Kesteloot H
    Acta Cardiol; 1985; 40(6):637-48. PubMed ID: 3879420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias.
    Falk RH; O'Brien JL
    Chest; 1984 Oct; 86(4):537-40. PubMed ID: 6383741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological effects of a new antiarrhythmic agent, lorcainide, on the isolated cardiac muscle fiber as compared with disopyramide.
    Shigenobu K; Atoda H; Asano T; Kasuya Y
    J Pharmacobiodyn; 1980 Dec; 3(12):677-85. PubMed ID: 7277183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Electrophysiologic effects of lorcainide (R 15889) in man].
    Touboul P; Atallah G; Kirkorian G
    Arch Mal Coeur Vaiss; 1981 Nov; 74(11):1333-40. PubMed ID: 6797372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.